CANF

USD

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

$1.080-0.030 (-2.703%)

Цена в режиме реального времени

Healthcare

Биотехнология

Израиль

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели

Фундаментальные показатели компании

Статистические данные торговли

Рыночные показатели

Открытие

$1.110

Максимум

$1.110

Минимум

$1.080

Объем

0.07M

Фундаментальные показатели компании

Рыночная капитализация

15.3M

Отрасль

Биотехнология

Страна

Israel

Статистические данные торговли

Средний объем

0.28M

Биржа

ASE

Валюта

USD

52-недельный диапазон

Минимум $0.98Текущая $1.080Максимум $4.69

Связанные новости

5 мая 2025 г. · 12:00

GlobeNewswire

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Просмотреть больше

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

17 апр. 2025 г. · 12:55

GlobeNewswire

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

Просмотреть больше

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

15 апр. 2025 г. · 11:08

Analyst Upgrades

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.

Просмотреть больше

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

14 апр. 2025 г. · 18:28

GlobeNewswire

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Просмотреть больше

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

14 апр. 2025 г. · 12:30

GlobeNewswire

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Просмотреть больше